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Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen
allergy coincide with the COVID-19 pandemic. Several considerations are important to allow
optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread
through sneezing, rhinorrhoea, and coughing.
This compact overview of recommendations by the EUFOREA expert teams on allergic airway
diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current
COVID-19 literature in association with the key words above and shared clinical experience of the
experts involved. It deals with similarities and differences between AR and coronavirus infection,
specific recommendations for allergic disease care in the COVID-19 era, including guidance on
AIT.
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Allergen-specific immunotherapyAcute COVID-19 infection and onset of seasonal confused with SAR, especially in those new to
allergic rhinitis (SAR) share a few similarities in their
phenotype, but also differences. Whereas COVID-
19 commonly presents as a flu-like illness with fe-
ver and persistent cough as its main symptoms,
there is evidence of milder disease, especially in
younger people. According to the World Health
Organisation (WHO), some patients may also have
a runny nose, sore throat, nasal congestion, and
aches and pains or diarrhoea. Some suffer pro-
found sudden and complete loss of smell and
taste.1 About 80% of COVID-19 sufferers experi-
ence a mild case – of similar severity to a common
cold – and recover without needing any special
treatment.2 This clinical presentation might beal National TNE Hospital and Department of Immunology, University
ege London, United Kingdom
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://doi.org/10.1016/j.waojou.2020.100124such symptoms. Fig. 1 shows the overlap and the
major differentiating features. Cough and fever
are the most prominent symptoms of COVID-19,
whereas conjunctivitis and itching point to
allergic rhinitis (AR) as the diagnosis.
Given the global COVID-19 threat to humankind
in spring 2020 and the fact that 44% of all trans-
mission occurs from asymptomatic people,3 it is
very important to keep SAR under the best
possible control so as to diminish symptoms,
particularly those of sneezing, rhinorrhoea, and
coughing, which could be responsible for viral
spread to others via aerosol formation in thoseReceived 17 April 2020; Received in revised from 28 April 2020; Accepted 7
May 2020
1939-4551/Crown Copyright © 2020 Published by Elsevier Inc. on behalf of
World Allergy Organization. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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http://doi.org/10.1016/j.waojou.2020.100124who do not realise that they also have COVID-19.
SAR patients are strongly recommended to keep
social distancing, to wear a mask to avoid aerosol
formation when sneezing or speaking, to carry
spare masks and tissues, and bin them safely after
use. It would be sensible, where possible, for SAR
patients to be tested for the SARS-CoV-2 virus,
since they could be potent viral spreaders.
Therapy for SAR is best started early and used
regularly throughout the relevant pollen season.
None of the recommended treatments for SAR are
contra-indicated, other than systemic corticoste-
roids. The EUFOREA treatment algorithm (Fig. 2)
provides useful guidance which remains relevant.
There is no contraindication to the use of
intranasal corticosteroids (INS). This is theFig. 2 Treatment algorithm for AR as proposed by EUFOREA, taking in
international guidelines. www.euforea.org. Treatments suggested are p
use of systemic corticosteroids which should be avoided as they may
Fig. 1 Similarities and differences between seasonal allergic rhinitis
and COVID- 19 symptomsconcerted view of over 90% of experts.4 INS do
not reduce immunity; in fact they normalize the
structure and function of the nasal mucosa5 and
do not in vivo adversely affect mucociliary
clearance.6 There are even preliminary data
indicating that some corticosteroids, e.g.,
ciclesonide and mometasone, may suppress
coronavirus replication.7 However, systemic
corticosteroids should be avoided, as they may
suppress the human immune system.
Similarly, asthma inhalers should be continued
as before and taken regularly, increasing the dose
if needed to maintain control in the pollen season.
Inhaled corticosteroids (ICS) and ICS combinations
with bronchodilators, long acting beta agonists
(LABA), are known to protect against virally-
induced asthma exacerbations and may be bene-
ficial in COVID-19.8 Also, treatment with
biologicals for patients with more severe asthma
and severe chronic rhinosinusitis with nasal
polyps should be continued to avoid aggravation
of these diseases as per guidelines.9 Although
the U.S. Centers for Disease Conrol and
Prevention (CDC) advises that, “People with
moderate to severe asthma may be at higher risk
of getting very sick from COVID-19. COVID-19
can affect your respiratory tract (nose, throat,
lungs), cause an asthma attack, and possibly leadto account the reality of patient phenotypes and existing
ossible during the COVID-19 pandemic with the exception of the
be immunosuppressive. The symbol ">" means “more than”
Volume 13, No. 5, May 2020 3to pneumonia and acute respiratory disease”,10
asthma may not be a potent risk factor.8 It is
already known that children, in whom respiratory
allergy is common, often have very mild disease.
In the first report from Wuhan, on 140 patients
with severe COVID-disease, none of the patients
reported AR or asthma despite a prevalence of AR
of nearly 20% in China.11,12 More recently, an
Italian report on 3200 COVID-19 positive
deceased patients did not mention asthma among
coexisting diseases.13
Ongoing allergen-specific immunotherapy (AIT)
should be continued, if feasible within the health
care system, as long as no COVID-19 infection has
been diagnosed. New AIT treatment with subcu-
taneous injections, subcutaneous immunotherapy
(SCIT), is not advised because of the necessity for
repeated visits to a physician or hospital; however,
the initiation of sublingual immunotherapy (SLIT),
which mandates only one initial dose under su-
pervision,14 should be preferred, or a switch to
SLIT from SCIT considered, when there is a
suitable alternative to SCIT for the allergen in
question. AIT should be performed only with
registered allergen products which have been
proven to be efficacious.15
Management of COVID-19 is supportive, with
experimental use of drugs, mainly in clinical trials
which may include patients with allergic airway
disease. Oral corticosteroids may be needed un-
der supervision in COVID-infected asthma patients
for severe virus-evoked exacerbations. Avoidance
of non-steroidal anti-inflammatory drugs (NSAIDs),
which was suggested for all possible patients,16
then revoked,17 remains vital in NSAID- sensitive
asthma.TAKE HOME MESSAGES
 Early mild COVID-19 symptoms may be
confused with or co-occurrent with AR.
 Proper treatment of AR is very important at this
time, as uncontrolled hay fever may increase the
risk of viral dissemination.
 Such therapy (including AIT) is not immunosup-
pressive and does not represent a risk factor for
more severe COVID-19-induced disease. Topical and inhaled corticosteroids may even be
beneficial or preventative for COVID-19
infection.
 Allergic airway disease is probably not a risk
factor for more severe COVID-19 disease; how-
ever, asthma control can worsen with viral
infections.
 Sudden and complete anosmia may be an early
sign of COVID-19 infection, differentiating it
from AR.
The latest updates on treatment recommenda-
tions for SAR, AIT, and smell loss are summarized
in expert videos disseminated via the EUFOREA
social media channels (https://twitter.com/
euforea), allowing the medical community to be
updated on medical consensus and expert opinion
regarding COVID-19 and respiratory allergy care.
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